Top

Cancer Chemotherapy and Pharmacology

Published in:

01-06-2011 | Mini Review

Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies

Authors: Simendra Singh, Alok K. Gupta

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2011

Abstract

Purpose

The diatomic radical nitric oxide (NO) has been the cause of intense debate with implication in carcinogenesis, tumour progression, invasion, angiogenesis and modulation of therapeutic responses. The tumour biology of NO is highly complex, and this review summarises the various protective and damaging mode of action of NO.

Methods

We reviewed all published literature addressing the complexities of the role of NO in the altered biology of cancer and evaluating promising therapeutic roles of NO/iNOS for anti-cancer therapy.

Results

The available experimental evidences highlight contrasting pro- and anti-tumour effects of iNOS expression, which appear to be reconciled by consideration of the concentrations of NO involved, the temporo-spatial mode of NO action, intracellular targets, cellular redox state and the timing of an apoptotic stimulus. Several clinical and experimental studies indicate that the presence of NO in tumour microenvironment is detrimental to tumour cell survival and metastasis. In contrast, numerous reports suggest that NO can have tumour-promoting effects. NO is a ‘double-edged sword’ in cancer, and this review offers insight into the dichotomous nature of NO and discuss the therapeutic gain that can be achieved by manipulating tumour NO.

Conclusions

NO may exert a biphasic response, such that when NO levels go beyond a critical concentration that would be suitable for tumour growth and survival, growth arrest and/or apoptotic pathways are initiated. These characteristics of NO have been exploited therapeutically with impressive effects in pre-clinical models of cancer to slow tumour growth and to enhance the efficacy of both chemotherapy and radiotherapy.

Knowles RG, Moncada S (1994) Nitric oxide synthases in mammals. Biochem J 298:249–258PubMed

Nathan C, Xie QW (1994) Regulation of biosynthesis of nitric oxide. J Biol Chem 269:13725–13728PubMed

Elfering SL, Sarkela TM, Giulivi C (2002) Biochemistry of mitochondrial nitric-oxide synthase. J Biol Chem 277:38079–38086PubMedCrossRef

Schmidt HH, Walter U (1994) NO at work. Cell 78:919–925PubMedCrossRef

Hibbs JBJ (1991) Synthesis of nitric oxide from l-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res Immunol 142:565–569PubMedCrossRef

Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh SI, Kimura T, Green SJ (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263:1612–1615PubMedCrossRef

Tendler DS, Bao C, Wang T, Huang EL, Ratovitski EA, Pardoll DA, Lowenstein CJ (2001) Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res 61:3682–3688PubMed

Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio LA (1995) Hypoxia responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182:1683–1693PubMedCrossRef

Kepp O, Tesniere A, Zitvogel L, Kroemer G (2008) The immunogenicity of tumor cell death. Curr Op Oncol 21:71–76CrossRef

10.

Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in Inflammation and Cancer. Annu Rev Immunol 28:367–388PubMedCrossRef

11.

Taguchi A, Blood DC, del Toro G et al (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354–360PubMedCrossRef

12.

Huttunen HJ, Kuja-Panula J, Sorci G et al (2000) Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 275:40096–40105PubMedCrossRef

13.

Kuniyasu H, Chihara Y, Kondo H (2003) Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104:722–777PubMedCrossRef

14.

Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41–44PubMedCrossRef

15.

Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA (1995) Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55:727–730PubMed

16.

Masri FA, Comhair SA, Koeck T, Xu W, Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, Erzurum SC, Aulak KS (2005) Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 172:597–605PubMedCrossRef

17.

Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82:1897–1903PubMedCrossRef

18.

Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F, Qian F (2001) Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg 67:709–713PubMed

19.

Hajri A, Metzger E, Vallat F, Coffy S, Flatter E, Evrard S, Marescaux J, Aprahamian M (1998) Role of nitric oxide in pancreatic tumour growth: in vivo and in vitro studies. Br J Cancer 78:841–849PubMedCrossRef

20.

Weninger W, Rendl M, Pammer J, Mildner M, Tschugguel W, Schneeberger C, Stürzl M, Tschachler E (1998) Nitric oxide synthases in Kaposi’s sarcoma are expressed predominantly by vessels and tissue macrophages. Lab Invest 78:949–955PubMed

21.

Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA (2000) Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 6:4768–4775PubMed

22.

Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S (1994) Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54:1352–1354PubMed

23.

Tschugguel W, Pustelnik T, Lass H, Mildner M, Weninger W, Schneeberger C, Jansen B, Tschachler E, Waldhör T, Huber JC, Pehamberger H (1999) Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. Br J Cancer 79:1609–1612PubMedCrossRef

24.

Loibl S, von Minckwitz G, Weber S, Sinn HP, Schini-Kerth VB, Lobysheva I, Nepveu F, Wolf G, Strebhart K, Kufmann M (2002) Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer 95:1191–1198PubMedCrossRef

25.

Dudzinski DM, Michel T (2007) Life history of eNOS: partners and pathways. Cardiovascular Res 75:247–260CrossRef

26.

Vakkala M, Paakko P, Soini Y (2000) eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol 17:667–671PubMed

27.

Zheng PP, Hop WC, Luider TM et al (2007) Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 62:40–48PubMedCrossRef

28.

Lim KH, Ancrile BB, Kashatus DF et al (2008) Tumour maintenance is mediated by eNOS. Nature 452:646–649PubMedCrossRef

29.

Gosink EC, Forsberg EJ (1993) Effects of ATP and bradykinin on endothelial cell Ca²⁺ homeostasis and formation of cGMP and prostacyclin. Am J Physiol Cell Physiol 265:C1620–C1629

30.

Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R (1996) Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 78:750–758PubMed

31.

Wang L, Shi GG, Yao JC et al (2005) Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 8:18–28PubMedCrossRef

32.

Ariel I, Hochberg A, Shochina M (1998) Endothelial nitric oxide synthase immunoreactivity in early gestation and in trophoblastic disease. J Clin Pathol 51:427–431PubMedCrossRef

33.

Bauer PM, Fulton D, Boo YC, Sorescu GP, Kemp BE, Jo H et al (2003) Compensatory phosphorylation and protein–protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric oxide synthase. J Biol Chem 278:14841–14849PubMedCrossRef

34.

Dudzinski DM, Igarashi J, Greif D, Michel T (2006) The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 46:235–276PubMedCrossRef

35.

Michell BJ, Chen ZZ, Tiganis T, Stapleton D, Katsis F et al (2001) Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276:17625–17628PubMedCrossRef

36.

Duda DG, Fukumura D, Jain RK (2004) Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 10:143–145PubMedCrossRef

37.

Chinje E, Stratford IJ (1997) The role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem 32:61–72PubMed

38.

Lincoln TM, Dey N, Sellak HH (2001) cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 91:1421–1430PubMed

39.

Brunori M, Giuffre A, Forte E, Mastronicola D, Barone MC, Sarti P (2004) Control of cytochrome c oxidase activity by nitric oxide. Biochim Biophys Acta 1655:365–371PubMedCrossRef

40.

Thomas DD, Liu X, Kantrow SP, Lancaster JR Jr (2001) The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O₂. Proc Natl Acad Sci (USA) 98:355–360CrossRef

41.

Cooper CE, Giulivi C (2007) Nitric oxide regulation of mitochondrial oxygen consumption II: molecular mechanism and tissue physiology. Am J Physiol Cell Physiol 292:C1993–C2003PubMedCrossRef

42.

Stuehr DJ, Santolini J, Wang ZQ, Wei CC, Adak S (2004) Update on mechanism and catalytic regulation in the NO synthases. J Biol Chem 279:36167–36170PubMedCrossRef

43.

Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, Isenberg JS (2006) The biphasic nature of nitric oxide responses in tumor biology. Antioxid Red Signal 8:1329–1337CrossRef

44.

Leon L, Jeannin J-F, Bettaieb A (2008) Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. Nitric Oxide 19:77–83PubMedCrossRef

45.

Park HS, Yu JW, Cho JH, Kim MS, Huh SH, Ryoo K, Choi EJ (2004) Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism. J Biol Chem 279:7584–7590PubMedCrossRef

46.

Sumbayev VV (2003) S-nitrosylation of thioredoxin mediates activation of apoptosis signal-regulating kinase 1. Arch Biochem Biophys 415:133–136PubMedCrossRef

47.

DelaTorre A, Schroeder RA, Kuo PC (1997) Alteration of NF-kappa B p50 DNA binding kinetics by S-nitrosylation. Biochem Biophy Res Comm 238:703–706CrossRef

48.

Gopalakrishna R, Chen ZH, Gundimeda U (1993) Nitric oxide and nitric oxide generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding. J Biol Chem 268:27180–27185PubMed

49.

Park HS, Huh SH, Kim MS, Lee SH, Choi EJ (2000) Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. Proc Natl Acad Sci 97:14382–14387PubMedCrossRef

50.

Teng KK, Esposito DK, Schwartz GD, Lander HM, Hempstead BL (1999) Activation of c-Ha-Ras by nitric oxide modulates survival responsiveness in neuronal PC12 cells. J Biol Chem 274:37315–37320PubMedCrossRef

51.

Xu L, Eu JP, Meissner G, Stamler JS (1998) Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279:234–237PubMedCrossRef

52.

MacMillan-Crow LA, Greendorfer JS, Vickers SM, Thompson JA (2000) Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma. Arch Biochem Biophys 377:350–356PubMedCrossRef

53.

West MB, Hill BG, Xuan YT, Bhatnagar A (2006) Protein glutathiolation by nitric oxide: an intracellular mechanism regulating redox protein modification. FASEB J 20:1715–1717PubMedCrossRef

54.

Maulik D, Ashraf QM, Mishra OP, Delivoria-Papadopoulos M (2008) Activation of p38 mitogen-activated protein kinase (p38 MAPK), extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) during hypoxia in cerebral cortical nuclei of guinea pig fetus at term: role of nitric oxide. Neurosci Lett 439:94–99PubMedCrossRef

55.

Lander HM, Ogiste JS, Pearce SF, Levi R, Novogrodsky A (1995) Nitric oxide stimulated guanine nucleotide exchange on p21ras. J Biol Chem 270:7017–7020PubMedCrossRef

56.

Duhé RJ, Evans GA, Erwin RA, Kirken RA, Cox GW, Farrar WL (1998) Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci 95:126–131PubMedCrossRef

57.

Tejedo JR, Cahuana GM, Ramirez R, Esbert M, Jiménez J, Sobrino F, Bedoya FJ (2004) Nitric oxide triggers the phosphatidylinositol 3-kinase/Akt survival pathway in insulin-producing RINm5F cells by arousing Src to activate insulin receptor substrate-1. Endocrinology 145:2319–2327PubMedCrossRef

58.

Lander HM, Jacovina AT, Davis RJ, Tauras JM (1996) Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J Biol Chem 271:19705–19709PubMedCrossRef

59.

Lala PK, Chakraborty C (2001) Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2:149–156PubMedCrossRef

60.

Pervin S, Singh R, Chaudhuri G (2008) Nitric Oide, N^ω-hydroxy-l-arginine and breast cancer. Nitric Oxide 19:103–106PubMedCrossRef

61.

Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA (2004) Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci 101:8894–8899PubMedCrossRef

62.

Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G (2007) Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 67:289–299PubMedCrossRef

63.

Schonhoff CM, Gaston B, Mannick JB (2003) Nitrosylation of cytochrome c during apoptosis. J Biol Chem 278:18265–18270PubMedCrossRef

64.

Millet A, Bettaieb A, Renaud F, Prevotat L, Hammann A, Solary E, Mignotte B, Jeannin JF (2002) Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. Gastroenterology 123:235–246PubMedCrossRef

65.

Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K, Gaston B (2001) S-Nitrosylation of mitochondrial caspases. J Cell Biol 154:1111–1116PubMedCrossRef

66.

Iyer AKV, Azad N, Wang L, Rojanasakul Y (2008) Role of S-nitrosylation in apoptosis resistance and angiogenesis. Nitric Oxide 19:146–151PubMedCrossRef

67.

Cook T, Wang Z, Alber S, Liu K, Watkins SC, Vodovotz Y, Billiar TR, Blumberg D (2004) Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 64:8015–8021PubMedCrossRef

68.

Zhang Y, Xiong Y (2001) A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292:1910–1915PubMedCrossRef

69.

Wang X, Zalcenstein A, Oren M (2003) Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. Cell Death Differ 10:468–476PubMedCrossRef

70.

Yakovlev VA, Bayden AS, Graves PR, Kellogg GE, Mikkelsen RB (2010) Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Biochemistry 49:5331–5339PubMedCrossRef

71.

Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci 1000:143–148CrossRef

72.

Cobbs CS, Samanta M, Harkins LE, Gillespie GY, Merrick BA, MacMillan-Crow LA (2001) Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: possible functional consequences. Arch Biochem Biophys 394:167–172PubMedCrossRef

73.

Xu W, Liu L, Smith GC, Charles IG (2000) Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol 2:339–345PubMedCrossRef

74.

Jones MK, Tsugawa K, Tarnawski AS, Baatar D (2004) Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Comm 318:520–528PubMedCrossRef

75.

Pervin S, Singh R, Freije WA, Chaudhuri G (2003) MKP-1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: implications in breast cancer. Cancer Res 63:8853–8860PubMed

76.

Chao JI, Kuo PC, Hsu TS (2004) Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 279:20267–20276PubMedCrossRef

77.

Garbán HJ, Bonavida B (2001) Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 167:75–81PubMed

78.

Garbán HJ, Bonavida B (2001) Nitric oxide disrupts H₂O₂-dependent activation of nuclear factor kappa B. role in sensitization of human tumor cells to tumor necrosis factor-alpha-induced cytotoxicity. J Biol Chem 276:8918–8923PubMedCrossRef

79.

Tozer GM, Prise VE, Chaplin DJ (1997) Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with l-arginine. Cancer Res 57:948–955PubMed

80.

Ishii Y, Ogura T, Tatemichi M, Fujisawa H, Otsuka F, Esumi H (2003) Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int J Cancer 103:161–168PubMedCrossRef

81.

Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H (2001) Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 92:439–451PubMed

82.

Aurello P, Rossi Del Monte S, D’Angelo F, Cicchini C, Ciardi A, Bellagamba R, Ravaioli M, Ramacciato G (2009) Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature. Oncol Res 17:405–411PubMedCrossRef

83.

Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (2003) Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 16:309–314PubMedCrossRef

84.

Ichinoe M, Mikami T, Shiraishi H, Okayasu I (2004) High microvascular density is correlated with high VEGF, iNOS and COX-2 expression in penetrating growth-type early gastric carcinomas. Histopathology 45:612–618PubMedCrossRef

85.

Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB III (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25:1539–1544PubMedCrossRef

86.

Cahlin C, Gelin J, Delbro D, Lönnroth C, Doi C, Lundholm K (2000) Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60:1742–1749PubMed

87.

Radomski MW, Jenkins DC, Holms L, Moncada S (1991) Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 51:6073–6078PubMed

88.

Dong Z, Staroselsky AH, Qi X, Xie K, Fidler IJ (1994) Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 54:789–793PubMed

89.

Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ (1995) Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181:1333–1343PubMedCrossRef

90.

Le X, Wei D, Huang S, Lancaster JR Jr, Xie K (2005) Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its upregulation of protumor factors. Proc Natl Acad Sci 102:8758–8763PubMedCrossRef

91.

Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li C-Q, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC (2007) JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110:709–718PubMedCrossRef

92.

Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH (2004) Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int J Cancer 108:47–53PubMedCrossRef

93.

Konovalova NP, Goncharova SA, Volkova LM, Rajewskaya TA, Eremenko LT, Korolev AM (2003) Nitric oxide donor increases the efficiency of cytostatic therapy and reatrds the development of drug resistance. Nitric Oxide 8:59–64PubMedCrossRef

94.

Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A (2005) Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65:516–525PubMed

95.

Muir CP, Adams MA, Graham CH (2006) Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Res Treat 96:169–176PubMedCrossRef

96.

Cook JA, Krishna MC, Pacelli R, DeGraff W, Liebmann J, Mitchell JB, Russo A, Wink DA (1997) Nitric oxide enhancement of melphalan-induced cytotoxicity. Br J Cancer 76:325–334PubMedCrossRef

97.

Adams DJ, Levesque MC, Weinberg JB, Smith KL, Flowers JL, Moore J, Colvin OM, Silber R (2001) Nitric oxide enhancement of fludarabine cytotoxicity for BCLL lymphocytes. Leukemia 15:1852–1859PubMed

98.

Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H (2006) Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 24:688–694PubMedCrossRef

99.

Huang LE, Bindra RS, Glazer PM, Harris AL (2007) Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 85:139–148PubMedCrossRef

100.

Brown JM (1999) The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863–5870PubMed

101.

Sandau KB, Fandrey J, Brune B (2001) Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 97:1009–1015PubMedCrossRef

102.

Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B (2003) Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Biol Cell 14:3470–3481PubMedCrossRef

103.

Mateo J, Garcia-Lecea M, Cadenas S, Hernandez C, Moncada S (2003) Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem J 376:537–544PubMedCrossRef

104.

Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437–447PubMedCrossRef

105.

McKeown SR, Cowen RL, Williams KJ (2007) Bioreductive drugs: from concept to clinic. Clin Oncol 19:427–442CrossRef

106.

Peters KB, Brown JM (1993) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62:5248–5253

107.

Chinje EC, Cowen RL, Feng J, Sharma SP, Wind NS, Harris AL, Stratford IJ (2003) Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 63:1248–1255PubMedCrossRef

108.

Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 12:119–134PubMedCrossRef

109.

Cowen RL, Singh S, Chinje EC, Al-Assah R, Harris P, Dunk C, Stratford IJ (2005) Adenoviral delivery of inducible nitric oxide synthase (NOSII) enhances AQ4 N/radiation cytotoxicity within hypoxic tumor cells. AACR Meeting Abstracts 314-A

110.

Robson T, Worthington J, McKeown SR, Hirst DG (2005) Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity. Technol Cancer Res Treat 4:343–361PubMed

111.

Gray LH, Green FO, Hawes CA (1958) Effect of nitric oxide on the radiosensitivity of tumour cells. Nature 182:952–953PubMedCrossRef

112.

Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC (1993) Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53:5845–5848PubMed

113.

Verovski VN, Van den Berge DL, Soete GA, Bols BL, Storme GA (1996) Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer 74:1734–1742PubMedCrossRef

114.

Wardman P, Rothkamm K, Folkes LK, Woodcock M, Johnston PJ (2007) Radiosensitization by nitric oxide at low radiation doses. Radiat Res 167:475–484PubMedCrossRef

115.

Singh S, Cowen RL, Chinje EC, Stratford IJ (2009) The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells. Radiat Res 171:572–580PubMedCrossRef

116.

Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, Li CY (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26:63–74PubMedCrossRef

117.

Abrams J (1992) Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol 70:30B–42BPubMedCrossRef

118.

Soler MN, Bobe P, Benihoud K, Lemaire G, Roos BA, Lausson S (2000) Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med 2:344–352PubMedCrossRef

119.

Wang Z, Cook T, Alber S, Liu K, Kovesdi I, Watkins SK, Vodovotz Y, Billiar TR, Blumberg D (2004) Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res 64:1386–1395PubMedCrossRef

120.

Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG (2004) Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 6:673–680PubMedCrossRef

121.

Halliwill JR, Minson CT, Joyner MJ (2000) Effect of systemic nitric oxide synthase inhibition on postexercise hypotension in humans. J Appl Physiol 89:1830–1836PubMed

122.

Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311–320PubMedCrossRef

Title: Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies
Authors: Simendra Singh
Alok K. Gupta
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1654-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2011

p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma

A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer